ArticleInternational journal of cancer2018
Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Surgical Management for Transposed Ovarian Recurrence of Cervical Cancer: A Systematic Review with Our Experience.Current oncology (Toronto, Ont.) · 2022Pooled it
- Ovarian metastasis in women with cervical carcinoma in stages IA to IIB: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.Obstetrics and gynecology · 2020Guideline
- Tumor lesion detection in patients with cervical cancer by indocyanine green near-infrared imaging.European journal of nuclear medicine and molecular imaging · 2023Trial
- Isolated ovarian metastasis in otherwise cervix-confined adenocarcinoma of the cervix: A rare clinical conundrum.Gynecologic oncology reports · 2026Article
- HPV status as a predictor of ovarian metastasis in cervical adenocarcinoma: implications for surgical decision-making.BMC women's health · 2026Article
- Adjuvant chemotherapy after radical hysterectomy yields comparable outcomes to chemoradiation for stage IB2-IIB and IIIC1-2 cervical cancer: a single-center retrospective study.Journal of gynecologic oncology · 2025Article
- Review
- How do we safely preserve ovaries in patients with cervical adenocarcinoma: risk factors and predictive models.Frontiers in oncology · 2024Article
- Recurrent early-stage squamous cell carcinoma cervical cancer presenting with isolated ovary metastasis: a rare case report.Annals of medicine and surgery (2012) · 2023Article
- Chinese Expert Consensus on ovarian function and fertility preservation of cervical cancer in pregnancy (2023).Frontiers in endocrinology · 2023Review
- Phase 1/2 study of concurrent chemoradiotherapy with weekly irinotecan hydrochloride for advanced/recurrence uterine cancer: A multi-institutional study of Kansai Clinical Oncology Group.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- Safety and Prognostic Impacts of Ovarian Preservation during Radical Hysterectomy for Early-Stage Adenocarcinoma and Adenosquamous Cervical Cancer.BioMed research international · 2020Article
- Association between the location of transposed ovary and ovarian dose in patients with cervical cancer treated with postoperative pelvic radiotherapy.Radiation oncology (London, England) · 2019Article
- Significance of Malignant Peritoneal Cytology on the Survival of Women with Early-Stage Cervical Cancer: A Japanese Gynecologic Oncology Group Study.Journal of clinical medicine · 2019Article
- Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2019Article
- Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer.Obstetrics and gynecology · 2019Article
- Study on value of ultrasonic elastography in diagnosis of clinical staging of cervical cancer and efficacy evaluation of radiotherapy.Oncology letters · 2019Article
- Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.Journal of clinical medicine · 2019Article
- Generation of uniform-sized multicellular tumor spheroids using hydrogel microwells for advanced drug screening.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 2 countries.
Funding
Abstract
This study seeks to identify risk factors associated with ovarian metastasis and to characterize a population with minimum risk of ovarian metastasis in young women with stage IB-IIB cervical cancer. This was a nation-wide multicenter retrospective study in Japan examining consecutive cases of surgically-treated women with clinical stage IB-IIB cervical cancer who had oophorectomy at radical hysterectomy (n = 5,697). Multivariable analysis was performed to identify independent risk factors for ovarian metastasis. Ovarian metastasis was seen in 70 (1.2%, 95% confidence interval 0.9-1.5) cases. In the entire cohort, adenocarcinoma, lympho-vascular space invasion, uterine corpus tumor invasion, and pelvic/para-aortic nodal metastases remained independent risk factors for ovarian metastasis (all, adjusted-p < 0.05). In a sensitivity analysis of 3,165 women aged <50 years (ovarian metastasis, 1.0%), adenocarcinoma, parametrial tumor involvement, uterine corpus tumor involvement, and pelvic/para-aortic nodal metastases remained independent risk factors for ovarian metastasis (all, adjusted-P < 0.05). In the absence of these five risk factors (representing 46.1% of women aged <50 years), the incidence of ovarian metastasis was 0.14%. With the presence of adenocarcinoma alone (representing 18.9% of women aged <50 years), the incidence of ovarian metastasis was 0.17% and was not associated with increased risk of ovarian metastasis compared to the subgroup without any risk factors (p = 0.87). In conclusion, nearly two thirds of women aged <50 years with clinical stage IB-IIB cervical cancer had no risk factor for ovarian metastasis or had adenocarcinoma alone: these subgroups had ovarian metastasis rates of around 0.1% and may be a candidate population for ovarian conservation at surgical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.